Quantcast

Latest Hodgkin's lymphoma Stories

2014-08-19 23:02:37

Lack of Access and Financial Burden May Contribute to Increased Mortality, CPIC Researchers Find Fremont, CA (PRWEB) August 19, 2014 Despite advances in treatment, lymphoma patients residing in low socioeconomic status (SES) neighborhoods experienced significantly worse survival than patients living in high SES neighborhoods, researchers at the Cancer Prevention Institute of California (CPIC) have reported. Those who live in the poorest communities have a 34 percent greater risk of dying...

2014-08-06 16:28:52

Participants to Produce Strategic Roadmap for Accelerating Lymphoma Treatment Advances WASHINGTON, Aug. 6, 2014 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, will hold its first ASH Meeting on Lymphoma Biology, a meeting focused on furthering the treatment of lymphoma, August 10-13 in Colorado Springs, Colorado. More than 350 lymphoma experts from around the...

2014-07-28 16:27:12

FLINT, Mich., July 28, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig(®) tablets. Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers. "We are pleased to partner with Gilead and be included in the limited panel of distribution for Zydelig," said Gary Kadlec, R.Ph, President of Diplomat. "Our expertise in...

2014-07-28 16:26:36

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018https://www.reportbuyer.com/product/2225690/Global-Non-Hodgkin-Lymphoma-Therapeutics-Market-2014-2018.htmlAbout Non-Hodgkin Lymphoma (NHL) and its Diagnostic ProceduresNon-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die....

2014-07-23 16:28:25

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies...

2014-07-17 12:29:31

-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments. As the leading fundraisers in the 2014 Man & Woman of the Year campaign, the 24(th) year for this prestigious program, these...

2014-07-14 12:55:18

The Lancet Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology. "The good news is that 5-year survival for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in...

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-11 12:28:56

Marketing Strategies That Educate Payers and Prescribers on Key Benefits of New Drugs Will Maximize Rapid Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., June 11, 2014 /PRNewswire/ -- Decision Resources Group finds that regimens based on Janssen's Velcade are the most commonly prescribed treatments for first-line multiple myeloma (MM), according to surveyed hematological oncologists from France, Germany, Italy and Spain. The exception is the United...

2014-06-10 08:30:25

CAMBRIDGE, Mass., June 10, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that an abstract on EPZ-6438 has been accepted for oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology, to be held August 10-13 in Colorado Springs, Colorado. The presentation will include findings characterizing the...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.